Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1993 Jan;69(1 Suppl):S54–S62. doi: 10.1136/hrt.69.1_suppl.s54

Modification of atherosclerosis by agents that do not lower cholesterol

John G F Cleland 1, Dennis M Krikler 1
PMCID: PMC1025260  PMID: 8427766

Full text

PDF
S54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BORCHGREVINK C. F. Long-term anticoagulant therapy in angina pectoris. A follow-up study. Lancet. 1962 Mar 3;1(7227):449–451. doi: 10.1016/s0140-6736(62)91417-4. [DOI] [PubMed] [Google Scholar]
  2. BOYLE E., BRAGDON J. H., BROWN R. K. Role of heparin in in vitro production of alpha1 lipoproteins in human plasma. Proc Soc Exp Biol Med. 1952 Nov;81(2):475–477. doi: 10.3181/00379727-81-19915. [DOI] [PubMed] [Google Scholar]
  3. Bonchek L. I., Boerboom L. E., Olinger G. N., Pepper J. R., Munns J., Hutchinson L., Kissebah A. H. Prevention of lipid accumulation in experimental vein bypass grafts by antiplatelet therapy. Circulation. 1982 Aug;66(2):338–341. doi: 10.1161/01.cir.66.2.338. [DOI] [PubMed] [Google Scholar]
  4. Böttiger L. E., Carlson L. A., Engstedt L., Orö L. Long-term heparin treatment in ischaemic heart disease. Effects on clinical condition and plasma lipids. Acta Med Scand. 1967 Aug;182(2):245–257. doi: 10.1111/j.0954-6820.1967.tb11519.x. [DOI] [PubMed] [Google Scholar]
  5. Carew T. E., Schwenke D. C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7725–7729. doi: 10.1073/pnas.84.21.7725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223(5):405–418. doi: 10.1111/j.0954-6820.1988.tb15891.x. [DOI] [PubMed] [Google Scholar]
  7. Carson S. N., Demling R. H., Esquivel C. O. Aspirin failure in symptomatic atherosclerotic carotid artery disease. Surgery. 1981 Dec;90(6):1084–1092. [PubMed] [Google Scholar]
  8. Chobanian A. V., Brecher P., Chan C. Effects of propranolol on atherogenesis in the cholesterol-fed rabbit. Circ Res. 1985 May;56(5):755–762. doi: 10.1161/01.res.56.5.755. [DOI] [PubMed] [Google Scholar]
  9. Chobanian A. V., Haudenschild C. C., Nickerson C., Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990 Mar;15(3):327–331. doi: 10.1161/01.hyp.15.3.327. [DOI] [PubMed] [Google Scholar]
  10. Cleland J. G., Henderson E., McLenachan J., Findlay I. N., Dargie H. J. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure. J Am Coll Cardiol. 1991 Mar 1;17(3):733–739. doi: 10.1016/s0735-1097(10)80192-5. [DOI] [PubMed] [Google Scholar]
  11. Cruickshank J. M., Smith J. C. The beta-receptor, atheroma and cardiovascular damage. Pharmacol Ther. 1989;42(3):385–404. doi: 10.1016/0163-7258(89)90032-6. [DOI] [PubMed] [Google Scholar]
  12. Daugherty A., Zweifel B. S., Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol. 1989 Oct;98(2):612–618. doi: 10.1111/j.1476-5381.1989.tb12635.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. ENGELBERG H., KUHN R., STEINMAN M. A controlled study of the effect of intermittent heparin therapy on the course of human coronary atherosclerosis. Circulation. 1956 Apr;13(4):489–498. doi: 10.1161/01.cir.13.4.489. [DOI] [PubMed] [Google Scholar]
  14. Elkayam U., Amin J., Mehra A., Vasquez J., Weber L., Rahimtoola S. H. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990 Dec;82(6):1954–1961. doi: 10.1161/01.cir.82.6.1954. [DOI] [PubMed] [Google Scholar]
  15. Esterbauer H., Puhl H., Dieber-Rotheneder M., Waeg G., Rabl H. Effect of antioxidants on oxidative modification of LDL. Ann Med. 1991;23(5):573–581. doi: 10.3109/07853899109150520. [DOI] [PubMed] [Google Scholar]
  16. Fuster V., Adams P. C., Badimon J. J., Chesebro J. H. Platelet-inhibitor drugs' role in coronary artery disease. Prog Cardiovasc Dis. 1987 Mar-Apr;29(5):325–346. doi: 10.1016/0033-0620(87)90001-6. [DOI] [PubMed] [Google Scholar]
  17. GRAHAM D. M., LYON T. P., GOFMAN J. W., JONES H. B., YANKLEY A., SIMONTON J., WHITE S. Blood lipids and human atherosclerosis. II. The influence of heparin upon lipoprotein metabolism. Circulation. 1951 Nov;4(5):666–673. doi: 10.1161/01.cir.4.5.666. [DOI] [PubMed] [Google Scholar]
  18. Gertler M. M., Leetma H. E., Koutrouby R. J., Johnson E. D. Long-term use of minidose heparin in post-myocardial infarction. Adv Exp Med Biol. 1975;52:341–350. doi: 10.1007/978-1-4684-0946-8_30. [DOI] [PubMed] [Google Scholar]
  19. Gey K. F., Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann N Y Acad Sci. 1989;570:268–282. doi: 10.1111/j.1749-6632.1989.tb14926.x. [DOI] [PubMed] [Google Scholar]
  20. Ginsburg R., Davis K., Bristow M. R., McKennett K., Kodsi S. R., Billingham M. E., Schroeder J. S. Calcium antagonists suppress atherogenesis in aorta but not in the intramural coronary arteries of cholesterol-fed rabbits. Lab Invest. 1983 Aug;49(2):154–158. [PubMed] [Google Scholar]
  21. Godfried S. L., Combs G. F., Jr, Saroka J. M., Dillingham L. A. Potentiation of atherosclerotic lesions in rabbits by a high dietary level of vitamin E. Br J Nutr. 1989 May;61(3):607–617. doi: 10.1079/bjn19890148. [DOI] [PubMed] [Google Scholar]
  22. Goldstein R. E., Boccuzzi S. J., Cruess D., Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991 Jan;83(1):52–60. doi: 10.1161/01.cir.83.1.52. [DOI] [PubMed] [Google Scholar]
  23. Hackett D., Davies G., Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J. 1988 Dec;9(12):1317–1323. doi: 10.1093/oxfordjournals.eurheartj.a062449. [DOI] [PubMed] [Google Scholar]
  24. Hajduczok Z. D., Weiss R. M., Stanford W., Marcus M. L. Determination of right ventricular mass in humans and dogs with ultrafast cardiac computed tomography. Circulation. 1990 Jul;82(1):202–212. doi: 10.1161/01.cir.82.1.202. [DOI] [PubMed] [Google Scholar]
  25. Henry P. D. Calcium antagonists as anti-atherosclerotic agents. Arteriosclerosis. 1990 Nov-Dec;10(6):963–965. doi: 10.1161/01.atv.10.6.963. [DOI] [PubMed] [Google Scholar]
  26. Hess H., Mietaschk A., Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet. 1985 Feb 23;1(8426):415–419. doi: 10.1016/s0140-6736(85)91144-4. [DOI] [PubMed] [Google Scholar]
  27. Jacques L. B. Heparin: an old drug with a new paradigm. Science. 1979 Nov 2;206(4418):528–533. doi: 10.1126/science.386509. [DOI] [PubMed] [Google Scholar]
  28. Janzon L., Bergqvist D., Boberg J., Boberg M., Eriksson I., Lindgärde F., Persson G., Almgren B., Fagher B., Kjellström T. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990 May;227(5):301–308. doi: 10.1111/j.1365-2796.1990.tb00164.x. [DOI] [PubMed] [Google Scholar]
  29. Jaques L. B. Drug prophylaxis in atherosclerosis. Artery. 1987;14(4):209–215. [PubMed] [Google Scholar]
  30. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928–5931. doi: 10.1073/pnas.84.16.5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kok F. J., van Poppel G., Melse J., Verheul E., Schouten E. G., Kruyssen D. H., Hofman A. Do antioxidants and polyunsaturated fatty acids have a combined association with coronary atherosclerosis? Atherosclerosis. 1991 Jan;86(1):85–90. doi: 10.1016/0021-9150(91)90101-8. [DOI] [PubMed] [Google Scholar]
  32. Kowala M. C., Nunnari J. J., Durham S. K., Nicolosi R. J. Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters. Atherosclerosis. 1991 Nov;91(1-2):35–49. doi: 10.1016/0021-9150(91)90185-6. [DOI] [PubMed] [Google Scholar]
  33. Leren T. P. Doxazosin increases low density lipoprotein receptor activity. Acta Pharmacol Toxicol (Copenh) 1985 Mar;56(3):269–272. doi: 10.1111/j.1600-0773.1985.tb01288.x. [DOI] [PubMed] [Google Scholar]
  34. Lichtlen P. R., Hugenholtz P. G., Rafflenbeul W., Hecker H., Jost S., Deckers J. W. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet. 1990 May 12;335(8698):1109–1113. doi: 10.1016/0140-6736(90)91121-p. [DOI] [PubMed] [Google Scholar]
  35. Loaldi A., Polese A., Montorsi P., De Cesare N., Fabbiocchi F., Ravagnani P., Guazzi M. D. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol. 1989 Sep 1;64(8):433–439. doi: 10.1016/0002-9149(89)90417-7. [DOI] [PubMed] [Google Scholar]
  36. Meade T. W., Mellows S., Brozovic M., Miller G. J., Chakrabarti R. R., North W. R., Haines A. P., Stirling Y., Imeson J. D., Thompson S. G. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986 Sep 6;2(8506):533–537. doi: 10.1016/s0140-6736(86)90111-x. [DOI] [PubMed] [Google Scholar]
  37. Neri Serneri G. G., Rovelli F., Gensini G. F., Pirelli S., Carnovali M., Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet. 1987 Apr 25;1(8539):937–942. doi: 10.1016/s0140-6736(87)90291-1. [DOI] [PubMed] [Google Scholar]
  38. Nilsson J., Sjölund M., Palmberg L., Von Euler A. M., Jonzon B., Thyberg J. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis. 1985 Dec;58(1-3):109–122. doi: 10.1016/0021-9150(85)90059-0. [DOI] [PubMed] [Google Scholar]
  39. Noronha-Dutra A. A., Steen-Dutra E. M., Woolf N. An antioxidant role for calcium antagonists in the prevention of adrenaline mediated myocardial and endothelial damage. Br Heart J. 1991 Jun;65(6):322–325. doi: 10.1136/hrt.65.6.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Orekhov A. N., Andrianova I. V., Rekhter M. D., Tertov V. V., Andreeva E. R., Ragimov S. E., Mironov A. A. Beta-blockers: propranolol, metoprolol, atenolol, pindolol, alprenolol and timolol, manifest atherogenicity on in vitro, ex vivo and in vivo models. Elimination of propranolol atherogenic effects by papaverine. Atherosclerosis. 1992 Jul;95(1):77–85. doi: 10.1016/0021-9150(92)90178-j. [DOI] [PubMed] [Google Scholar]
  41. Orekhov A. N., Ruda MYa, Baldenkov G. N., Tertov V. V., Khashimov K. A., Ryong L. H., Lyakishev A. A., Kozlov S. G., Tkachuk V. A., Smirnov V. N. Atherogenic effects of beta blockers on cells cultured from normal and atherosclerotic aorta. Am J Cardiol. 1988 May 1;61(13):1116–1117. doi: 10.1016/0002-9149(88)90138-5. [DOI] [PubMed] [Google Scholar]
  42. Ostlund-Lindqvist A. M., Lindqvist P., Bräutigam J., Olsson G., Bondjers G., Nordborg C. Effect of metoprolol on diet-induced atherosclerosis in rabbits. Arteriosclerosis. 1988 Jan-Feb;8(1):40–45. doi: 10.1161/01.atv.8.1.40. [DOI] [PubMed] [Google Scholar]
  43. Overturf M. L., Sybers H. D., Smith S. A. Captopril-induced hyperreninemia in cholesterol-fed rabbits. Res Commun Chem Pathol Pharmacol. 1985 Feb;47(2):229–253. [PubMed] [Google Scholar]
  45. Packham M. A., Cazenave J. P., Kinlough-Rathbone R. L., Mustard J. F. Drug effects on platelet adherence to collagen and damaged vessel walls. Adv Exp Med Biol. 1978;109:253–276. doi: 10.1007/978-1-4684-0967-3_14. [DOI] [PubMed] [Google Scholar]
  46. Packham M. A., Cazenave J. P., Kinlough-Rathbone R. L., Mustard J. F. Drug effects on platelet adherence to collagen and damaged vessel walls. Adv Exp Med Biol. 1978;109:253–276. doi: 10.1007/978-1-4684-0967-3_14. [DOI] [PubMed] [Google Scholar]
  47. Parthasarathy S. Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water-soluble probucol derivative. J Clin Invest. 1992 May;89(5):1618–1621. doi: 10.1172/JCI115757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Parthasarathy S., Khoo J. C., Miller E., Barnett J., Witztum J. L., Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci U S A. 1990 May;87(10):3894–3898. doi: 10.1073/pnas.87.10.3894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., Warlow C., Hafner B., Thompson E., Norton S. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988 Jan 30;296(6618):313–316. doi: 10.1136/bmj.296.6618.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  51. Raizner A. E., Hust R. G., Lewis J. M., Winters W. L., Jr, Batty J. W., Roberts R. Transluminal coronary angioplasty in the elderly. Am J Cardiol. 1986 Jan 1;57(1):29–32. doi: 10.1016/0002-9149(86)90946-x. [DOI] [PubMed] [Google Scholar]
  52. Reed D., Abbott R. D., Smucker M. L., Kaul S. Prediction of outcome after mitral valve replacement in patients with symptomatic chronic mitral regurgitation. The importance of left atrial size. Circulation. 1991 Jul;84(1):23–34. doi: 10.1161/01.cir.84.1.23. [DOI] [PubMed] [Google Scholar]
  53. Ridker P. M., Manson J. E., Buring J. E., Goldhaber S. Z., Hennekens C. H. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study. Am Heart J. 1991 Dec;122(6):1588–1592. doi: 10.1016/0002-8703(91)90275-m. [DOI] [PubMed] [Google Scholar]
  54. Salerno D. M., Fifield J., Farmer C., Hodges M. Pirmenol: an antiarrhythmic drug with unique electrocardiographic features--a double-blind placebo-controlled comparison with quinidine. Clin Cardiol. 1991 Jan;14(1):25–32. doi: 10.1002/clc.4960140107. [DOI] [PubMed] [Google Scholar]
  55. Schwartz C. J., Valente A. J., Kelley J. L., Sprague E. A., Edwards E. H. Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin Thromb Hemost. 1988 Apr;14(2):189–195. doi: 10.1055/s-2007-1002775. [DOI] [PubMed] [Google Scholar]
  56. Singh R. B., Rastogi S. S., Verma R., Laxmi B., Singh R., Ghosh S., Niaz M. A. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ. 1992 Apr 18;304(6833):1015–1019. doi: 10.1136/bmj.304.6833.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990 Jul 19;323(3):147–152. doi: 10.1056/NEJM199007193230302. [DOI] [PubMed] [Google Scholar]
  58. Smith T. L., Kummerow F. A. Effect of dietary vitamin E on plasma lipids and atherogenesis in restricted ovulator chickens. Atherosclerosis. 1989 Feb;75(2-3):105–109. doi: 10.1016/0021-9150(89)90166-4. [DOI] [PubMed] [Google Scholar]
  59. Srinivasan S., Aaron R., Chopra P. S., Lucas T., Sawyer P. N. Effect of thrombotic and antithrombotic drugs on the surface charge characteristics of canine blood vessels: in vivo and in vitro studies. Surgery. 1968 Oct;64(4):827–833. [PubMed] [Google Scholar]
  60. Stehbens W. E. An appraisal of cholesterol feeding in experimental atherogenesis. Prog Cardiovasc Dis. 1986 Sep-Oct;29(2):107–128. doi: 10.1016/0033-0620(86)90021-6. [DOI] [PubMed] [Google Scholar]
  61. Stein Y., Stein O., Delplanque B., Fesmire J. D., Lee D. M., Alaupovic P. Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels. Atherosclerosis. 1989 Feb;75(2-3):145–155. doi: 10.1016/0021-9150(89)90171-8. [DOI] [PubMed] [Google Scholar]
  62. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation. 1991 Sep;84(3):1420–1425. doi: 10.1161/01.cir.84.3.1420. [DOI] [PubMed] [Google Scholar]
  63. Stender S., Stender I., Nordestgaard B., Kjeldsen K. No effect of nifedipine on atherogenesis in cholesterol-fed rabbits. Arteriosclerosis. 1984 Jul-Aug;4(4):389–394. doi: 10.1161/01.atv.4.4.389. [DOI] [PubMed] [Google Scholar]
  64. Stiegler H., Hess H., Mietaschk A., Trampisch H. J., Ingrisch H. Einfluss von Ticlopidin auf die periphere obliterierende Arteriopathie. Dtsch Med Wochenschr. 1984 Aug 17;109(33):1240–1243. doi: 10.1055/s-2008-1069356. [DOI] [PubMed] [Google Scholar]
  65. Vinazzer H., Stemberger A., Haas S., Blümel G. Influence of heparin; of different heparin fractions and of a low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res. 1982 Aug 1;27(3):341–352. doi: 10.1016/0049-3848(82)90081-0. [DOI] [PubMed] [Google Scholar]
  66. Ware J. A., Johnson P. C., Smith M., Salzman E. W. Inhibition of human platelet aggregation and cytoplasmic calcium response by calcium antagonists: studies with aequorin and quin2. Circ Res. 1986 Jul;59(1):39–42. doi: 10.1161/01.res.59.1.39. [DOI] [PubMed] [Google Scholar]
  67. Waters D., Lespérance J., Francetich M., Causey D., Théroux P., Chiang Y. K., Hudon G., Lemarbre L., Reitman M., Joyal M. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990 Dec;82(6):1940–1953. doi: 10.1161/01.cir.82.6.1940. [DOI] [PubMed] [Google Scholar]
  68. Wilhelmsen L., Berglund G., Elmfeldt D., Fitzsimons T., Holzgreve H., Hosie J., Hörnkvist P. E., Pennert K., Tuomilehto J., Wedel H. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987 Oct;5(5):561–572. doi: 10.1097/00004872-198710000-00009. [DOI] [PubMed] [Google Scholar]
  69. Williams R. J., Motteram J. M., Sharp C. H., Gallagher P. J. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. 1992 Jun;94(2-3):153–159. doi: 10.1016/0021-9150(92)90240-h. [DOI] [PubMed] [Google Scholar]
  70. Wöll E., Weiss H., Waldegger S., Lang F. Effect of calcium channel antagonists on cell membrane potential oscillations and proliferation of cells expressing the ras oncogene. Eur J Pharmacol. 1992 Feb 25;212(1):105–107. doi: 10.1016/0014-2999(92)90080-n. [DOI] [PubMed] [Google Scholar]
  71. ver Donck L., Wouters L., Olbrich H. G., Mutschler E., Borgers M. Nebivolol increases survival in cardiomyopathic hamsters with congestive heart failure. J Cardiovasc Pharmacol. 1991 Jul;18(1):1–3. doi: 10.1097/00005344-199107000-00001. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES